Remove Clinical Trials Remove Conditions Remove Document Remove Extraction
article thumbnail

Ohio Gives Another Shot at Expanding Qualifying Conditions

Veriheal

Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. Medical cannabis is now available to residents in Ohio who meet one of 22 qualifying conditions laid out by House Bill 523. Strict Guidelines Must be Met Before Conditions Will Be Considered.

article thumbnail

Article: Intellectual Property Due Diligence in Psychedelics

Cannabis Law Report

For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. However, that does not mean that the path to patents is closed off.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52
article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. Now, psychedelic research is booming.

History 119
article thumbnail

CBD Science Update

Project CBD

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Related story Can CBD Help Your Condition? Preclinical promise.

CBD 218
article thumbnail

CBD Science Update

Project CBD

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Related story Can CBD Help Your Condition? Preclinical promise.

CBD 177
article thumbnail

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

Since 2017, several clinical trials and observational studies have examined the efficacy of MCs in the pediatric population for a few indications, most of them focused on CBD efficacy in Dravet syndrome 28 , 29 , 30. A reason for exclusion for every individual study was documented. Data extraction. Results.

Safety 52